HRP20041108B1 - Peptidi povezani sa tumorom koji se vežu na mhc molekule - Google Patents

Peptidi povezani sa tumorom koji se vežu na mhc molekule

Info

Publication number
HRP20041108B1
HRP20041108B1 HRP20041108AA HRP20041108A HRP20041108B1 HR P20041108 B1 HRP20041108 B1 HR P20041108B1 HR P20041108A A HRP20041108A A HR P20041108AA HR P20041108 A HRP20041108 A HR P20041108A HR P20041108 B1 HRP20041108 B1 HR P20041108B1
Authority
HR
Croatia
Prior art keywords
tumors
mhc molecules
relates
peptide
concerning
Prior art date
Application number
HRP20041108AA
Other languages
English (en)
Croatian (hr)
Inventor
Toni Weinschenk
Hans Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HRP20041108A2 publication Critical patent/HRP20041108A2/hr
Publication of HRP20041108B1 publication Critical patent/HRP20041108B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
HRP20041108AA 2002-05-29 2003-03-27 Peptidi povezani sa tumorom koji se vežu na mhc molekule HRP20041108B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225144A DE10225144A1 (de) 2002-05-29 2002-05-29 An MHC-Moleküle bindende Tumor-assoziierte Peptide
PCT/EP2003/003181 WO2003102023A1 (de) 2002-05-29 2003-03-27 An mhc-moleküle bindende tumor-assoziierte peptide

Publications (2)

Publication Number Publication Date
HRP20041108A2 HRP20041108A2 (en) 2005-10-31
HRP20041108B1 true HRP20041108B1 (hr) 2013-11-08

Family

ID=29557592

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20041108AA HRP20041108B1 (hr) 2002-05-29 2003-03-27 Peptidi povezani sa tumorom koji se vežu na mhc molekule

Country Status (15)

Country Link
US (5) US7396904B2 (https=)
EP (5) EP1734048B1 (https=)
JP (5) JP4472520B2 (https=)
AT (5) ATE466872T1 (https=)
AU (2) AU2003224001B2 (https=)
CA (5) CA2736972C (https=)
CY (5) CY1108507T1 (https=)
DE (6) DE10225144A1 (https=)
DK (5) DK1734048T3 (https=)
ES (5) ES2317379T3 (https=)
HR (1) HRP20041108B1 (https=)
PL (5) PL206306B1 (https=)
PT (5) PT1507795E (https=)
SI (5) SI1734049T1 (https=)
WO (1) WO2003102023A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
ES2633389T3 (es) * 2003-01-30 2017-09-21 Survac Aps Péptidos derivados de survivina y uso de los mismos
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
ATE458747T1 (de) * 2003-12-01 2010-03-15 Meiji Dairies Corp Angiontensin converting enzyme hemmendes peptid
JP2007515924A (ja) * 2003-12-15 2007-06-21 アウレリウム バイオファーマ インク． ビメンチン指向性診断法、および、多剤耐性を示す腫瘍性疾患の治療法
DE102004011503A1 (de) * 2004-01-28 2005-09-15 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung und Quantifizierung von tumor-assoziierten Peptiden
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
PL1642905T3 (pl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
PL2565204T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
WO2009129498A2 (en) * 2008-04-17 2009-10-22 Immuneregen Biosciences, Inc. Substance p and analogs thereof as a cancer immunogenic composition adjuvant
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
CN101451975B (zh) * 2008-12-29 2012-01-25 浙江大学 一种检测胃癌预后与分期血清蛋白质的方法
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
PL3456339T3 (pl) * 2013-08-05 2022-03-21 Immatics Biotechnologies Gmbh Nowa immunoterapia przeciwko szeregu nowotworom, takim jak rak płuc, w tym nsclc
US20160310583A1 (en) * 2013-10-03 2016-10-27 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
ES2928331T3 (es) 2013-11-13 2022-11-17 Univ Minnesota Composiciones de variantes de anexina II y métodos
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2983924T3 (es) 2015-03-27 2024-10-28 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
KR102184377B1 (ko) 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
WO2019160383A1 (ko) * 2018-02-19 2019-08-22 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
BR102018010523A2 (pt) * 2018-05-23 2020-04-28 Univ Estadual Campinas Unicamp peptídeo, composição farmacêutica compreendendo o mesmo e uso

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739009A (en) * 1996-12-12 1998-04-14 Incyte Pharmaceuticals, Inc. Adipocyte-specific differentiation-related protein
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
WO2001062787A1 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of bipolar affective disorder
WO2002050103A2 (en) * 2000-12-20 2002-06-27 Glaxosmithkline Biologicals S.A. Tumour-related antigens
US20030170719A1 (en) * 2000-12-28 2003-09-11 Akio Matsuda NF-kappa B activating gene
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003048323A2 (en) * 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens

Also Published As

Publication number Publication date
ES2317379T3 (es) 2009-04-16
CA2736926C (en) 2015-11-17
ES2350461T3 (es) 2011-01-24
EP2006294A1 (de) 2008-12-24
US20080057077A1 (en) 2008-03-06
CA2736921C (en) 2013-09-03
DE50313004D1 (de) 2010-09-30
CY1111174T1 (el) 2015-06-11
JP2010099080A (ja) 2010-05-06
JP5042300B2 (ja) 2012-10-03
CA2736921A1 (en) 2003-12-11
AU2010200689A1 (en) 2010-03-18
HRP20041108A2 (en) 2005-10-31
CA2736926A1 (en) 2003-12-11
DK1734048T3 (da) 2009-02-23
AU2010200689B2 (en) 2012-07-12
CA2487137C (en) 2013-02-19
US8399613B2 (en) 2013-03-19
PL211159B1 (pl) 2012-04-30
EP1734049B1 (de) 2008-12-03
DK2006294T3 (da) 2010-12-13
PL211157B1 (pl) 2012-04-30
CY1108680T1 (el) 2014-04-09
EP1734049A1 (de) 2006-12-20
JP2010099078A (ja) 2010-05-06
AU2003224001A1 (en) 2003-12-19
SI2006294T1 (sl) 2010-11-30
PL373700A1 (en) 2005-09-05
SI1734048T1 (sl) 2009-02-28
EP1734048B1 (de) 2008-12-17
US20080051347A1 (en) 2008-02-28
CA2487137A1 (en) 2003-12-11
EP2014673B1 (de) 2010-05-05
DE50312701D1 (de) 2010-06-17
ATE478088T1 (de) 2010-09-15
DE50310952D1 (de) 2009-01-29
US20100184211A1 (en) 2010-07-22
EP2006294B1 (de) 2010-08-18
US8536304B2 (en) 2013-09-17
US20050222390A1 (en) 2005-10-06
JP5042301B2 (ja) 2012-10-03
SI1734049T1 (sl) 2009-02-28
ES2317378T3 (es) 2009-04-16
JP2010099079A (ja) 2010-05-06
PT2014673E (pt) 2010-08-04
ES2348468T3 (es) 2010-12-07
SI2014673T1 (sl) 2010-09-30
EP1507795B1 (de) 2008-10-08
US7396904B2 (en) 2008-07-08
JP2010088449A (ja) 2010-04-22
PT1507795E (pt) 2008-12-26
CA2736974A1 (en) 2003-12-11
CY1108673T1 (el) 2014-04-09
DE10225144A1 (de) 2003-12-18
PL210356B1 (pl) 2012-01-31
SI1507795T1 (sl) 2009-04-30
DK1507795T3 (da) 2008-12-08
PT1734048E (pt) 2009-01-02
US7666984B2 (en) 2010-02-23
ES2314196T3 (es) 2009-03-16
AU2003224001B2 (en) 2010-03-11
JP4472520B2 (ja) 2010-06-02
PL206306B1 (pl) 2010-07-30
JP5042303B2 (ja) 2012-10-03
CA2736974C (en) 2014-09-02
CA2736972C (en) 2014-08-05
JP5042302B2 (ja) 2012-10-03
DE50310882D1 (de) 2009-01-15
US7763711B2 (en) 2010-07-27
US20100183644A1 (en) 2010-07-22
CA2736972A1 (en) 2003-12-11
EP2014673A1 (de) 2009-01-14
CY1108507T1 (el) 2014-04-09
WO2003102023A1 (de) 2003-12-11
ATE416188T1 (de) 2008-12-15
DK2014673T3 (da) 2010-08-30
PT2006294E (pt) 2010-11-12
PL211158B1 (pl) 2012-04-30
ATE466872T1 (de) 2010-05-15
DK1734049T3 (da) 2009-01-19
ATE410442T1 (de) 2008-10-15
EP1734048A1 (de) 2006-12-20
ATE417859T1 (de) 2009-01-15
CY1110723T1 (el) 2015-06-10
PT1734049E (pt) 2008-12-26
DE50310613D1 (de) 2008-11-20
EP1507795A1 (de) 2005-02-23
JP2006511196A (ja) 2006-04-06

Similar Documents

Publication Publication Date Title
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
Michels et al. Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
HUP0203506A2 (hu) Terápiás ágensként használható módosított peptidek
MEP57508A (en) Binding agents which inhibit myostatin
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
HUP0401534A2 (hu) Módosított humán IX. faktor
WO2004020462A1 (ja) Ｃｘｃｒ４拮抗薬およびその用途
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
JP2010524849A5 (https=)
EP2189471A4 (en) FOXM1 PEPTIDE AND MEDICAMENT THEREFOR
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
CN102037005B (zh) 改善治疗功效的新光学纯化合物
JP2006506942A5 (https=)
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
MY209484A (en) Cpg amphiphiles and uses thereof
JPH06228199A (ja) 血液脳関門通過可能なペプチド結合体
JPH06500114A (ja) 組織再生促進及び癌治療用の生物活性ｅｇｆペプチド
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
JP2019038772A5 (https=)
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
JP2005508875A5 (https=)
JP2018510213A5 (https=)
DK0811068T3 (da) Humane DNase I varianter

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20180319

Year of fee payment: 16

PBON Lapse due to non-payment of renewal fee

Effective date: 20190327